/EUCR

EUCR Stock - Eucrates Biomedical Acquisition Corp.

Q: What is the analyst price target for EUCR?

Analyst price target information is not currently available for EUCR.

Q: What is EUCR's market cap?

Market capitalization information is not currently available for EUCR.

Financial Services|Shell Companies|NASDAQ

$10.04+0.00%

+$0.00 (+0.00%) • Apr 26

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $11.04

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EUCR

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.07

52W High$10.25

52W Low$9.87

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A
Operating Income	$-699,000	$-743,000	$8,594
Net Income	$5.54M	$3.82M	$8,594
Net Margin	N/A	N/A	N/A
EPS	$1.86	$1.28	$0.00

Company Overview

Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York.

Earnings History & Surprises

EUCR

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$0.18

Q4 2022

EPS Surprise History

Q1 21

No data

Q2 21

No data

Q3 21

No data

Q4 21

No data

Q1 22

No data

Q2 22

No data

Q3 22

No data

Q4 22

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2022	Dec 31, 2022	—	$0.18	—	—
Q3 2022	Sep 30, 2022	—	$0.09	—	—
Q2 2022	Jun 30, 2022	—	$0.07	—	—
Q1 2022	Mar 31, 2022	—	$0.21	—	—
Q4 2021	Dec 31, 2021	—	$0.21	—	—
Q3 2021	Sep 30, 2021	—	$0.07	—	—
Q2 2021	Jun 30, 2021	—	$0.05	—	—
Q1 2021	Mar 31, 2021	—	$0.15	—	—
Q4 2020	Dec 31, 2020	—	$0.00	—	—

Frequently Asked Questions about EUCR

What is EUCR's current stock price?

Eucrates Biomedical Acquisition Corp. (EUCR) is currently trading at $10.04 per share. The stock has moved +0.00% today.

What is the analyst price target for EUCR?

No analyst price targets are currently available for this stock.

What sector is Eucrates Biomedical Acquisition Corp. in?

Eucrates Biomedical Acquisition Corp. operates in the Financial Services sector, specifically within the Shell Companies industry. The company is traded on the NASDAQ exchange.

What is EUCR's market cap?

Eucrates Biomedical Acquisition Corp. has a market capitalization of $0.04 billion, making it a small-cap company.

Does EUCR pay dividends?

No, Eucrates Biomedical Acquisition Corp. does not currently pay a dividend to shareholders.